POAG development: risk factors

Article

Patients with thicker corneas are less likely to progress to primary open angle glaucoma (POAG) from ocular hypertension (OHT), according to a study published in the June 2008 issue of Contact Lens and Anterior Eye.

Patients with thicker corneas are less likely to progress to primary open angle glaucoma (POAG) from ocular hypertension (OHT), according to a study published in the June 2008 issue of Contact Lens and Anterior Eye.

Neel Bhatt of Bolton Royal Infirmary, Bolton, United Kingdom and colleagues conducted a cohort study with a ten-year retrospective case note review (n=58) and performed multivariate logistic regression analysis to assess the roles of intraocular pressure (IOP), age and gender on the risk of disease progression in OHT.

Of 116 eyes, 50 progressed to POAG; the team noted that thicker central corneal thickness (CCT; ≤579 µm), higher IOP at presentation (≥26 mmHg) and increasing age (≥75 years) were associated with a greater likelihood of progression.

The team concluded that IOP, age, and CCT, but not gender, are risk factors for progression of OHT to POAG.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.